Effects of different molecular subtypes and tumor biology on the prognosis of medulloblastoma

Aras, Yavuz; Dölen, Duygu; Celik, Ayca Iribas; Kılıç, Gozde; Kebudi, Rejin; Ünverengil, Gökçen; Sabancı, Pulat Akın; İzgi, Ali Nail

doi:10.1007/s00381-021-05350-1

Cited by 4 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LASSO regression, on the other hand, selected Age, Histological, Radiotherapy, Chemotherapy, Metastasis, Tumor texture, and Hydrocephalus. The variables screened through these three methods have been previously validated to be associated with prognosis in existing research on medulloblastoma (Archer et al, 2017;Guo et al, 2020;Aras et al, 2021;Franceschi et al, 2021). This aligns with our study findings.…”

Section: Discussionsupporting

confidence: 88%

Survival nomogram for medulloblastoma and multi-center external validation cohort

Li,

Gong

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Medulloblastoma (MB) is a highly malignant neuroepithelial tumor occurring in the central nervous system. The objective of this study was to establish an effective prognostic nomogram to predict the overall survival (OS) of MB patients.Materials and methods: The nomogram was developed using data from a retrospective cohort of 280 medulloblastoma patients (aged 3–18 years) identified from Beijing Tiantan Hospital between 2016 and 2021 as the training cohort. To validate the performance of the nomogram, collaborations were formed with eight leading pediatric oncology centers across different regions of China. A total of 162 medulloblastoma patients meeting the inclusion criteria were enrolled from these collaborating centers. Cox regression analysis, best subsets regression, and Lasso regression were employed to select independent prognostic factors. The nomogram’s prognostic effectiveness for overall survival was assessed using the concordance index, receiver operating characteristic curve, and calibration curve.Results: In the training cohort, the selected variables through COX regression, best subsets regression, and Lasso regression, along with their clinical significance, included age, molecular subtype, histological type, radiotherapy, chemotherapy, metastasis, and hydrocephalus. The internally and externally validated C-indexes were 0.907 and 0.793, respectively. Calibration curves demonstrated the precise prediction of 1-, 3-, and 5-year OS for MB patients using the nomogram.Conclusion: This study developed a nomogram that incorporates clinical and molecular factors to predict OS prognosis in medulloblastoma patients. The nomogram exhibited improved predictive accuracy compared to previous studies and demonstrated good performance in the external validation cohort. By considering multiple factors, clinicians can utilize this nomogram as a valuable tool for individualized prognosis prediction and treatment decision-making in medulloblastoma patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Survival nomogram for medulloblastoma and multi-center external validation cohort

Li,

Gong

2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Aras et. al [23] also reported similar findings where 87.5% of non-WNT/ non-SHH MB cases showed classic histology while the rest showed LC/A histology. Eid and Heabah [20] found that higher rates of LC/A histology were represented in non-WNT/non-SHH molecular subgroup forming the majority of the group (54.2%) while the rest of the cases (45.8%) showed classic histology.…”

Section: Clinical Characteristicssupporting

confidence: 53%

“…Aras et. al [23] reported that 71% of non-WNT/non-SHH MB patients in their study were of high risk. Yehia et.…”

Section: Clinical Characteristicsmentioning

confidence: 92%

“…Aras et. al [23] also reported that 75% of non-WNT/non-SHH patients presented by metastasis. Similar findings were reported by Remke et.…”

Section: Clinical Characteristicsmentioning

confidence: 96%

“…Aras et. al [23] found different results with higher survival rates for non-WNT/non-SHH molecular subgroup than other molecular subgroups. They also reported that there was no statistically significant difference among OS and EFS of molecular subgroups.…”

Section: Clinical Characteristicsmentioning

confidence: 96%

See 2 more Smart Citations

Clinicopathological Characteristics of non-WNT/non-SHH Medulloblastoma Cases in a Pediatric Egyptian Cohort

Hamam

Abdelzaher

Nassra

et al. 2023

Asian Pac J Cancer Care

View full text Add to dashboard Cite

Objective: Medulloblastoma is the most common malignant pediatric brain tumor. It has a great impact on global health. Although, current treatment modalities improve patients` survival rates, survivors suffer from long term treatment related morbidity. Major advances have changed molecular understanding of medulloblastoma with the emergence of the molecular classification of medulloblastoma that has been introduced in WHO classification of CNS tumors. Non-WNT/non-SHH molecular subgroup is the most common molecular subgroup representing more than 60% of medulloblastoma cases. The present study aims to describe the clinical, pathological, and survival characteristics of pediatric patients with non-WNT/non-SHH MB. Results: A total of 36 non-WNT/non-SHH MB cases were detected. The age of the patients ranged between 2 to 18 years. 14 patients (39%) were standard risk while 22 patients (61%) were high risk. Microscopic evaluation showed that 34 cases (94.4%) were of classic histology, while 2 cases (5.6%) were of LC/A histology. The 5-year overall survival of the 36 non-WNT/non-SHH cases detected was 55% and the 5-year event free survival was 40%. Conclusion: The clinical, pathological, and molecular characteristics of pediatric patients with non-WNT/non-SHH molecular subgroup of medulloblastoma described in the present study were mostly similar to those reported in the literature.

show abstract

Posterior Fossa Tumours in the First Year of Life: A Two-Centre Retrospective Study

et al. 2022

View full text Add to dashboard Cite

Posterior fossa tumours (PFTs) in infants are very rare, and information on these tumours is scarce in the literature. This retrospective study reports their pathological characteristics and describes surgical aspects and treatment outcomes. A two-centre cohort of infants with PFTs treated from 2007 to 2018 was retrospectively reviewed. Patient characteristics, clinical, and treatment data were reviewed. Survival curves for progression-free survival (PFS) and overall survival (OS) were generated. Thirty-three infants were retrieved. There were 11 low grade and 22 high-grade tumours. The most common presenting symptom was intracranial hypertension. Fifteen children out of thirty-three progressed. Five-year PFS was significantly lower in children with high-grade tumours (38.3%) than those with low-grade tumours (69.3%), p = 0.030. High-grade pathology was the only predictor of progression (HR 3.7, 95% CI 1.1–13.31), p = 0.045. Fourteen children with high-grade tumours died, with a 5-year OS of 55.25%. PFTs in children below one year of age still represent a unique challenge. Infants with high-grade tumours display the worst outcomes and the lowest survival, indicating that more effective strategies are needed.

show abstract

Effects of different molecular subtypes and tumor biology on the prognosis of medulloblastoma

Cited by 4 publications

References 48 publications

Survival nomogram for medulloblastoma and multi-center external validation cohort

Survival nomogram for medulloblastoma and multi-center external validation cohort

Clinicopathological Characteristics of non-WNT/non-SHH Medulloblastoma Cases in a Pediatric Egyptian Cohort

Posterior Fossa Tumours in the First Year of Life: A Two-Centre Retrospective Study

Contact Info

Product

Resources

About